Mr. Cesar Fuentes had a kidney tumor surgically removed; lymph node and bone metastases years later led to immune and targeted therapy which have provided significant tumor shrinkage and generally mild, manageable side effects.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.